CN114177299B - 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 - Google Patents
包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 Download PDFInfo
- Publication number
- CN114177299B CN114177299B CN202111545151.1A CN202111545151A CN114177299B CN 114177299 B CN114177299 B CN 114177299B CN 202111545151 A CN202111545151 A CN 202111545151A CN 114177299 B CN114177299 B CN 114177299B
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- cancer
- ezh2
- gsk126
- scd1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 91
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 title claims abstract description 79
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title claims abstract description 78
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 title claims abstract description 46
- 101100041816 Homo sapiens SCD gene Proteins 0.000 title claims abstract description 40
- 101150097713 SCD1 gene Proteins 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 21
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 claims abstract description 73
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 65
- NVUJDKDVOZVALT-UHFFFAOYSA-N 2-methyl-5-[6-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]pyridazin-3-yl]-1,3,4-thiadiazole Chemical compound S1C(C)=NN=C1C1=CC=C(N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)N=N1 NVUJDKDVOZVALT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000002708 enhancing effect Effects 0.000 claims abstract description 6
- 201000001441 melanoma Diseases 0.000 claims description 15
- 201000007270 liver cancer Diseases 0.000 claims description 10
- 208000014018 liver neoplasm Diseases 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 60
- 210000004881 tumor cell Anatomy 0.000 description 18
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 230000037356 lipid metabolism Effects 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 239000002207 metabolite Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000010609 cell counting kit-8 assay Methods 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 206010017758 gastric cancer Diseases 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 201000011549 stomach cancer Diseases 0.000 description 7
- 101000713288 Homo sapiens Solute carrier family 22 member 5 Proteins 0.000 description 6
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 description 6
- 108010087230 Sincalide Proteins 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 description 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 206010023825 Laryngeal cancer Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 description 4
- 230000006372 lipid accumulation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- WFOFPVXMPTVOTJ-UHFFFAOYSA-N 2-[6-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]pyridazin-3-yl]-5-methyl-1,3,4-oxadiazole Chemical compound O1C(C)=NN=C1C1=CC=C(N2CCC(CC2)OC=2C(=CC=C(F)C=2)Cl)N=N1 WFOFPVXMPTVOTJ-UHFFFAOYSA-N 0.000 description 3
- DPYTYQFYDLYWHZ-UHFFFAOYSA-N 4-(2-chlorophenoxy)-n-[3-(methylcarbamoyl)phenyl]piperidine-1-carboxamide Chemical compound CNC(=O)C1=CC=CC(NC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=C1 DPYTYQFYDLYWHZ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100032050 Elongation of very long chain fatty acids protein 2 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 101000921368 Homo sapiens Elongation of very long chain fatty acids protein 2 Proteins 0.000 description 3
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 108010017842 Telomerase Proteins 0.000 description 3
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- TVGUBMHUHTULAD-UHFFFAOYSA-N [5-[6-[4-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]pyridazin-3-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound FC(C1(CCN(CC1)C1=CC=C(N=N1)C1=NN=C(O1)CO)C1=CC=C(C=C1)C(F)(F)F)(F)F TVGUBMHUHTULAD-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- HPODOLXTMDHLLC-QGZVFWFLSA-N n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-1-[(1r)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)(F)F)CC3)C=2C)=C1OC HPODOLXTMDHLLC-QGZVFWFLSA-N 0.000 description 3
- PVTIQVJHZDSETN-UHFFFAOYSA-N n-[2-[6-[(3,4-dichlorophenyl)methylamino]-2-(4-methoxyphenyl)-3-oxopyrido[2,3-b]pyrazin-4-yl]ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(C(N(CCNC(C)=O)C1=N2)=O)=NC1=CC=C2NCC1=CC=C(Cl)C(Cl)=C1 PVTIQVJHZDSETN-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 2
- 206010023347 Keratoacanthoma Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 102000017946 PGC-1 Human genes 0.000 description 2
- 108700038399 PGC-1 Proteins 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000017055 digestive system neuroendocrine neoplasm Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 229940073193 lirametostat Drugs 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002705 metabolomic analysis Methods 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 description 1
- PFHDWRIVDDIFRP-UHFFFAOYSA-N 6-cyano-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-1-pentan-3-ylindole-4-carboxamide Chemical compound C1=C(C#N)C=C2N(C(CC)CC)C=CC2=C1C(=O)NCC1=C(C)C=C(C)NC1=O PFHDWRIVDDIFRP-UHFFFAOYSA-N 0.000 description 1
- 102100035623 ATP-citrate synthase Human genes 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 235000008317 Condalia obovata Nutrition 0.000 description 1
- 244000147935 Condalia obovata Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- ULNXAWLQFZMIHX-UHFFFAOYSA-N GSK343 Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=C(N=CC=2)N2CCN(C)CC2)C(C)C)=C1CCC ULNXAWLQFZMIHX-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000782969 Homo sapiens ATP-citrate synthase Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 description 1
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 description 1
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 1
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000009815 adipogenic differentiation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 201000011025 embryonal testis carcinoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 208000022669 mucinous neoplasm Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000007282 progesterone-receptor negative breast cancer Diseases 0.000 description 1
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950004774 tazemetostat Drugs 0.000 description 1
- 206010062123 testicular embryonal carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 208000028010 vulval Paget disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于医药领域，提供了一种增强EZH2抑制剂抗肿瘤作用的药物组合物，所述药物组合物包含EZH2抑制剂和SCD1抑制剂，其中所述SCD1抑制剂增强所述EZH2抑制剂抗实体瘤的作用。本发明还提供了所述药物组合物的相关制剂及其在制备抗肿瘤药物中的用途。实验结果表明，将EZH2抑制剂GSK126与SCD1抑制剂MF‑438联合用于治疗B16F10和SMMC7721细胞，发现与MF‑438的联用确实可以显著增强GSK126对细胞增殖的抑制作用。本发明为临床上能够安全、有效、方便、经济地使用EZH2抑制剂治疗实体瘤提供一种新思路，临床应用前景良好。
Description
技术领域
本发明属于医药领域，具体涉及一种包含EZH2抑制剂和SCD1抑制剂的抗肿瘤药物组合物及其在制备抗肿瘤药物中的用途。
背景技术
Zeste基因增强子同源物2(Enhancer of zeste homolog 2，EZH2)是多梳抑制复合物2(polycomb repressive complex 2，PRC2)的催化亚基，发挥组蛋白甲基转移酶的作用。许多疾病(如肿瘤)中都存在EZH2的异常，多个证据表明EZH2与多种癌症的发生和进展以及预后不良有关。EZH2过表达主要见于实体瘤，包括前列腺癌、乳腺癌、膀胱癌、子宫内膜癌和黑色素瘤等，高水平的EZH2表达常常与这些类型肿瘤的高侵袭性、肿瘤进展期、具有较差的临床结果和预后相关联。
与正常细胞不同，肿瘤细胞通过致癌突变直接或间接调节细胞代谢重编程，以满足它们的生存和增殖需求。表观遗传机制可以调节参与代谢基因的表达，从而改变细胞的代谢特征。EZH2作为组蛋白修饰的关键调节因子，参与调节肿瘤细胞的多种代谢活动，从而影响肿瘤的进程。
EZH2在肿瘤细胞也能促进脂质合成。在含有端粒酶逆转录酶(telomerasereverse transcriptase，TERT)突变神经胶质瘤细胞中，TERT和EZH2水平成正相关，TERT-EZH2相互协同激活过氧化物酶体增殖物激活受体γ共激活因子1-α(Peroxisomeproliferator-activated receptor gamma coactivator 1-α，PGC-1α)，而脂肪酸合成酶(FASN)的表达依赖于PGC-1α，从而EZH2通过TERT-EZH2网络促进了脂肪酸合成和蓄积。并且有研究称肿瘤细胞中高水平脂肪酸可以通过负调节DNA损伤修复(DDR)途径促进肿瘤发生和耐药性。但相反的是，EZH2抑制剂DZNep会诱导在非酒精性脂肪肝细胞和某些癌细胞系(如乳腺癌)中的脂质积累。为了阐明这种差异，有学者利用原代人类、小鼠前脂肪细胞和特异性敲除脂肪细胞中EZH2的小鼠，研究了EZH2在脂肪细胞分化和脂质代谢中的作用。他们发现抑制EZH2或基因缺失促进了载脂蛋白E(Apolipoprotein E，ApoE)基因表达上调，并伴随着脂蛋白依赖性脂质的吸收，最终导致胞质内脂质蓄积。但不影响脂肪细胞标志物基因的表达和脂肪细胞分化。这与以往研究中发现EZH2促进小鼠脂肪祖细胞脂肪形成分化的结论是相悖的。因此，EZH2在肿瘤细胞中对脂代谢的调节作用还不是很清楚，EZH2是如何影响到脂肪酸、甘油三酯、酮体等脂代谢产物的，以及这些代谢产物在肿瘤进程中又扮演着怎么样的角色，还需要进一步的探讨。
通过高通量筛选已经获得了许多高效和具有选择性的EZH2催化抑制剂，如EPZ005687、EI1、GSK343、GSK126等，其结构中几乎全部都带有2-吡啶酮基团。目前已开发了许多EZH2抑制剂作为潜在的抗癌药物。其中，CPI1205(Lirametostat)已通过临床试验测试，EPZ-6438(Tazemetostat)于2020年被FDA批准用于治疗上皮样肉瘤。但是，在EZH2过表达的实体瘤中，EZH2抑制剂效果不佳，如胶质瘤和黑素瘤中Ras通路和SWI/SNF的同时突变能够逃逸EZH2抑制剂的抗肿瘤效应。因此，研究人员试图尝试通过采用联合多种药物或多种抗肿瘤治疗手段的治疗策略改善EZH2抑制剂的疗效(参见，例如，Zhang Tengrui,etal.,Symphony of epigenetic and metabolic regulation-interaction between thehistone methyltransferase EZH2 and metabolism of tumor,Clinical Epigenetics,2020,12:72)。
此外，本发明人此前的研究成果显示，由EZH2介导的表观遗传调控和代谢改变显示了在癌细胞中的协同作用。本发明人初步发现EZH2抑制剂治疗效果不佳可能是由于脂质代谢失调导致的。硬脂酰辅酶A去饱和酶1(stearoyl-coenzyme A desaturase 1,SCD1)最初被发现与肥胖、脂肪肝、血脂异常以及胰岛素抵抗等代谢综合征相关，但是随着脂质组学和基因组学的发展，已逐渐认识到SCD1及其产物MUFA在肿瘤中的重要作用。研究发现，SCD1与肿瘤发生、发展密切相关，目前SCD1已成为一个新型的抗肿瘤治疗靶点。
鉴于以上的研究背景，本发明人推测联合SCD1抑制剂可能在针对某些与脂代谢相关的抗肿瘤药物的联合疗法中具有重要作用，这很可能为解决EZH2抑制剂治疗效果不佳提供了一种新思路。
发明内容
本发明的目的在于针对EZH2抑制剂对于实体瘤的活性不佳的问题，提供了一种能够增强EZH2抑制剂抗肿瘤作用的包含EZH2抑制剂和SCD1抑制剂的药物组合物，为临床上能够安全、有效、方便、经济地使用EZH2抑制剂治疗实体瘤提供一种新思路。
具体地，通过以下几个方面的技术方案实现了本发明：
在第一个方面中，本发明提供了一种增强EZH2抑制剂抗肿瘤作用的药物组合物，所述药物组合物包含EZH2抑制剂和SCD1抑制剂，其中所述SCD1抑制剂增强所述EZH2抑制剂抗实体瘤的作用。
作为可选方式，在上述药物组合物中，所述EZH2抑制剂与所述SCD1抑制剂的质量比为10：10-10：1，实质上，所述EZH2抑制剂与所述SCD1抑制剂在药物组合物中的用量比例可以由临床医师根据患者所患癌症的种类根据临床经验确定。
优选地，所述EZH2抑制剂与所述SCD1抑制剂的质量比选自10：10、10：9、10：8、10：7、10：6、10：5、10：4、10：3、10：2或10：1。
作为可选方式，在上述药物组合物中，所述实体瘤选自：乳腺癌、前列腺癌、黑色素瘤、骨肉瘤、神经母细胞瘤、胰腺癌、肺癌、横纹肌肉瘤、尤因肉瘤、膀胱癌、结肠癌、肝癌、卵巢癌、宫颈癌、鼻咽癌、喉癌、胃癌、肾癌、头颈部肿瘤、食管癌、睾丸癌或甲状腺癌。
优选地，所述实体瘤选自：乳腺癌、黑色素瘤、肺癌、结肠癌、肝癌或胃癌。
作为可选方式，在上述药物组合物中，所述EZH2抑制剂选自：Tazemetostat(EPZ-6438)、GSK126、Lirametostat(CPI-1205)、SHR2554或PF-06821497；所述SCD1抑制剂选自：CAY-10566、A939572、CVT-11127、MF-438、T-3764518、Plurisin#1、BZ36或Abbott#7n。
作为可选方式，在上述药物组合物中，优选地，所述EZH2抑制剂为GSK126，所述SCD1抑制剂为MF-438。
在第二个方面中，本发明提供了一种增强EZH2抑制剂抗肿瘤作用的药物制剂，所述药物制剂由治疗有效量的上述第一个方面所述的药物组合物和药学上可接受的载体制成。
作为可选方式，在上述药物制剂中，所述药物制剂为口服制剂。
优选地，所述口服制剂是口服液、片剂、粉剂、胶囊剂或颗粒剂。
在第三个方面中，本发明提供了上述第一个方面所述的药物组合物或者上述第二个方面所述的药物制剂在制备抗肿瘤药物中的用途。
作为可选方式，在上述用途中，所述肿瘤是实体瘤。
所述实体瘤选自：乳腺癌、前列腺癌、黑色素瘤、骨肉瘤、神经母细胞瘤、胰腺癌、肺癌、横纹肌肉瘤、尤因肉瘤、膀胱癌、结肠癌、肝癌、卵巢癌、宫颈癌、鼻咽癌、喉癌、胃癌、肾癌、头颈部肿瘤、食管癌、睾丸癌或甲状腺癌，优选地，所述实体瘤选自：乳腺癌、黑色素瘤、肺癌、结肠癌、肝癌或胃癌。
在第四个方面中，本发明提供了SCD1抑制剂在制备增强EZH2抑制剂抗实体瘤疗效的药物中的用途。
所述实体瘤选自：乳腺癌、前列腺癌、黑色素瘤、骨肉瘤、神经母细胞瘤、胰腺癌、肺癌、横纹肌肉瘤、尤因肉瘤、膀胱癌、结肠癌、肝癌、卵巢癌、宫颈癌、鼻咽癌、喉癌、胃癌、肾癌、头颈部肿瘤、食管癌、睾丸癌或甲状腺癌。
优选地，所述实体瘤选自：乳腺癌、黑色素瘤、肺癌、结肠癌、肝癌或胃癌。
所述EZH2抑制剂选自：Tazemetostat(EPZ-6438)、GSK126、Lirametostat(CPI-1205)、SHR2554或PF-06821497。
所述SCD1抑制剂选自：CAY-10566、A939572、CVT-11127、MF-438、T-3764518、Plurisin#1、BZ36或Abbott#7n。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一赘述。
本发明相对于现有技术，具有以下有益效果：
本发明人首次发现通过将EZH2抑制剂与SCD1抑制剂联合使用，能够显著增强EZH2抑制剂治疗实体瘤的疗效，并在此基础上提供了一种能够增强EZH2抑制剂抗肿瘤作用的包含EZH2抑制剂和SCD1抑制剂的药物组合物，为临床上能够安全、有效、方便、经济地使用EZH2抑制剂治疗实体瘤提供一种新思路，临床应用前景良好。
附图说明
图1：血液系统肿瘤比实体瘤对GSK126更敏感。(A)通过Incucyte S3监测GSK126(10-20μM)处理中B16F10，Huh7和SMMC7721细胞的增殖情况，每组设置6次重复；(B)通过CCK-8测定法测量GSK126(200nM-24μM)处理24h和48h后Daudi和THP-1细胞的活力，每组设置5次重复；(C)在无或有GSK126处理(6μM，12μM)48h后对B16F10细胞的蛋白质印迹分析(WB)，H3用作组蛋白内参。每组设置5-6次重复，*P<0.05，**P<0.01，***P<0.001，ns表示无统计学差异。
图2：黑色素瘤细胞B16F10对GSK126的敏感性较低。(A)细胞划痕实验显示了GSK126(10μM)治疗对B16F10细胞迁移能力的影响，每组设置3次重复；(B-C)通过流式细胞术(C)和膜联蛋白V染色(Annexin V)测定法检测GSK126(10、13、15μM)对B16F10细胞凋亡率的影响。每组设置3次重复，*P<0.05，**P<0.01，***P<0.001，ns表示无统计学差异。
图3：GSK126导致黑色素瘤B16F10细胞中6种脂肪酸显著升高。
图4：GSK126治疗后的小鼠出现脂质蓄积。(A)对照组和GSK126治疗组的荷瘤小鼠肝脏组织切片H&E和油红O染色，右图为阴性或阳性染色面积的统计结果(每组3次重复)；(B)对照组和GSK126治疗组的荷瘤小鼠血清中TG水平(每组5次重复)；(C-D)通过RT-qPCR和WB检测GSK126处理的HCC细胞中脂肪酸合成代谢相关基因的mRNA(C)和蛋白质(D)水平(每组3次重复)。每组3-5次重复，*P＜0.05，**P<0.01。
图5：GSK126对Daudi细胞代谢谱的影响。(A)基于代谢分析的正交偏最小二乘判别分析(OPLS-DA)得分图(每组6次重复)。C：对照，G：GSK126治疗。(B)验证OPLS-DA模型的得分图(R2Y＝0.973；Q2Y＝0.931)。(C)代谢组学中每类代谢物的数量。(D)人类蛋白质图谱(HPA)数据库分析展现不同癌症患者的SCD蛋白表达水平。(E)通过CCK-8试剂盒(每组3次重复)分析棕榈酸处理后Daudi细胞的活力。每组3-6次重复，*P<0.05，**P<0.01。
图6：与SCD1抑制剂联用增强了GSK126对癌细胞的抑制作用。(A)DMSO和GSK126处理的Daudi细胞之间的差异代谢物。热图显示了VIP(变量权重值)值大于1的71种差异代谢物的比例丰度。代谢物类别以不同颜色显示。(B)GSK126处理的Daudi细胞中四种显着减少的脂肪酸。(C)通过RT-qPCR检测GSK126处理的Daudi细胞中脂质代谢基因的mRNA水平(每组3次重复)。(D)通过CCK-8试剂盒(每组5次重复)分析GSK126和棕榈酸处理的Daudi细胞的活力。(E)通过CCK-8试剂盒(每组5次重复)分析GSK126和硬脂酸处理的Daudi细胞的活力。(F)通过IncuCyte S3监测GSK126和MF-438处理的B16F10和SMMC7721细胞的增殖曲线(每组5次重复)。(G)CCK-8试剂盒检测GSK126和MF-438处理的B16F10和SMMC7721细胞的活力。CI由CompuSyn软件计算。CI<0.9表示协同作用，CI>1.1表示拮抗作用。(H)小鼠荷瘤实验示意图。(I-J)负荷B16F10细胞小鼠的肿瘤重量(I)和肿瘤生长曲线(J)。每2天用游标卡尺测量肿瘤体积。肿瘤体积＝(长*宽*宽)/2。(K)所有实验组的代表性肿瘤图片。每组3-8次重复，*P<0.05，**P<0.01，***P<0.001。
具体实施方式
本发明人在对EZH2在肿瘤细胞中对脂代谢的调节作用机制以及EZH2抑制剂抗肿瘤作用机制的深入研究中，通过大量筛选，首次发现通过将EZH2抑制剂与SCD1抑制剂联合使用，能够显著增强EZH2抑制剂治疗实体瘤的疗效。在此基础上完成了本发明。
如本文所用，本发明药物组合物中的EZH2抑制剂和SCD1抑制剂可以在同一药物制剂中施用，也可以在不同药物制剂中施用。在不同药物制剂中施用的情况下，EZH2抑制剂和SCD1抑制剂的剂型可以是相同的，也可以是不同的。并且，EZH2抑制剂和SCD1抑制剂可以同时或顺序施用。
如本文所用，“SCD1”是调节肿瘤细胞脂质构成的关键枢纽，同时也在肿瘤细胞生长、存活、恶性转化信号转导通路中发挥重要作用。以SCD1为靶点的抑制剂可抑制肿瘤细胞增殖、诱导细胞凋亡并逆转肿瘤细胞化疗耐药，在临床前实验中显示一定的抗肿瘤活性。在本发明中，“SCD1抑制剂”选自：CAY-10566、A939572、CVT-11127、MF-438、T-3764518、Plurisin#1、BZ36或Abbott#7n。
本发明药物组合物治疗的肿瘤的非限制性实例可以包括但不限于：胆道癌(例如，胆管癌)、膀胱癌、乳腺癌(例如，乳腺腺癌、乳腺乳头状癌、乳腺癌、乳腺髓样癌、三阴乳腺癌、HER2阴性乳腺癌、HER2阳性乳腺癌、男性乳腺癌、晚期转移性乳腺癌、孕激素受体阴性乳腺癌、孕激素受体阳性乳腺癌、复发性乳腺癌)、脑癌(例如，脑膜瘤；神经胶质瘤，例如星形细胞瘤、少突胶质瘤；髓母细胞瘤)、支气管癌、宫颈癌(例如，宫颈腺癌)、绒毛膜癌、结直肠癌(例如，结肠癌、直肠癌、结直肠腺癌)、上皮癌、子宫内膜癌(例如，子宫癌、子宫肉瘤)、食道癌(例如，食道腺癌、巴雷特氏腺癌)、尤因氏肉瘤、眼癌(例如，眼内黑色素瘤、视网膜母细胞瘤)、胆囊癌、胃癌(例如，胃腺癌)、胃肠道间质肿瘤(GIST)、多形胶质母细胞瘤、头颈癌(例如，头颈鳞状细胞癌、口腔癌(例如，口腔鳞状细胞癌(OSCC))、咽喉癌(例如，喉癌、咽癌、鼻咽咽、口咽癌))、肾癌(例如，肾母细胞瘤，又称Wilms肿瘤，肾细胞癌)、肝癌(例如，肝细胞癌(HCC)、恶性肝癌)、肺癌(例如，支气管癌、小细胞癌(SCLC)、非小细胞肺癌(NSCLC)、肺腺癌)、平滑肌肉瘤(LMS)、骨髓增生异常综合征(MDS)、间皮瘤、神经内分泌癌(例如，胃肠胰腺神经内分泌肿瘤(GEP-NET)、类癌肿瘤)、骨肉瘤、卵巢癌(例如，囊腺癌、卵巢胚胎癌、卵巢腺癌)、乳头状腺癌、胰腺癌(例如，胰腺腺癌、导管内乳头状粘液性肿瘤(IPMN)、胰岛细胞肿瘤)、阴茎癌(例如，阴茎和阴囊的佩吉特氏病)、前列腺癌(例如，前列腺腺癌)、直肠癌、横纹肌肉瘤、皮肤癌(例如，鳞状细胞癌(SCC)、角膜棘皮瘤(KA)、黑色素瘤、基底细胞癌(BCC))、小肠癌(例如，阑尾癌)、软组织肉瘤(例如，恶性纤维组织细胞瘤(MFH)、脂肪肉瘤、软骨肉瘤、纤维肉瘤)、皮脂腺癌、汗腺癌、滑膜瘤、睾丸癌(例如，精原细胞瘤、睾丸胚胎癌)、甲状腺癌(例如，甲状腺乳头状癌、乳头状甲状腺癌(PTC)、甲状腺髓样癌)、尿道癌、阴道癌和外阴癌(例如，外阴佩吉特氏病)。
如本文所用，本发明药物制剂的剂型为片剂、胶囊剂、颗粒剂、口服液或吸入剂。优选地，本发明的剂型为片剂或胶囊剂。
如本文所用，本发明的“药学上可接受的载体”是指药物制剂领域常规的药物载体，选自填充剂、粘合剂、崩解剂、润滑剂、助悬剂、润湿剂、色素、矫味剂、溶剂、表面活性剂中的一种或几种。
本发明所述填充剂包括但不限于淀粉、微晶纤维素、蔗糖、糊精、乳糖、糖粉、葡萄糖等；所述润滑剂包括但不限于硬脂酸镁、硬脂酸、氯化钠、油酸钠、月桂醇硫酸钠、泊洛沙姆等；所述粘合剂包括但不限于水、乙醇、淀粉浆、糖浆、羟丙基甲基纤维素、羧甲基纤维素钠、海藻酸钠、聚乙烯吡咯烷酮等；所述崩解剂包括但不限于淀粉泡腾混合物即碳酸氢钠和枸橼酸、酒石酸、低取代羟丙基纤维素等；所述助悬剂包括但不限于多糖如金合欢胶、琼脂、藻酸、纤维素醚和羧甲基甲壳酯等；所述溶剂包括但不限于水、平衡的盐溶液等。
优选地，可以将本发明的药物制成各种固体口服制剂、液体口服制剂等。药剂学可接受的口服剂固体制剂有：普通片剂、分散片、肠溶片、颗粒剂、胶囊剂、滴丸、散剂等，口服液体制剂有口服液、乳剂等。或者，也可以将本发明的药物制成吸入剂等局部应用剂型。
上述各种剂型可以根据药物制剂领域的常规工艺制备而成。
在上文所述的药物组合物、药物制剂和医药用途中，对于“EZH2抑制剂”和“SCD1抑制剂”的给药时间、给药次数和给药频率等等，需要根据病情的具体诊断结果而定，这在本领域技术人员掌握的技术范围之内。
下面参照具体的实施例对本发明做进一步说明。应当理解，此处所描述的具体实施例仅用于解释本发明，并不用于限定本发明的范围。
实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件，或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可通过正规渠道购买得到的常规产品。
下面实施例中的实验方法，如无特殊说明，均为常规方法。下述实施例中所用的试验材料，如无特殊说明，均为市售产品。
除非另外说明，否则本发明中涉及的百分比和份数均为重量百分比和重量份数。
实施例：
1.多种实体瘤细胞系对EZH2抑制剂GSK126的敏感性较低
为了准确评估实体肿瘤细胞对EZH2抑制剂的反应性，首先利用IncuCyte
Live-Cell Analysis System检测了不同浓度的GSK126对黑色素瘤细胞B16F10和肝癌细胞Huh7和SMMC-7721增殖的影响。结果表明，GSK126以剂量依赖性方式抑制细胞增殖，而较高浓度10μM的GSK126的作用效果不佳(图1A)。
在相同的条件下，CCK-8细胞增殖实验结果表明，血液系统肿瘤细胞Daudi和THP-1经10μM的GSK126处理24h和48h后增殖却受到明显抑制。特别是Burkitt淋巴瘤细胞Daudi对1μM的GSK126就已经非常敏感(图1B)。与其他研究一致，我们发现实体瘤细胞系通常对EZH2抑制剂不敏感，而许多研究表明，大多数接受GSK126治疗的血液学癌细胞系的IC50(半数最大抑制浓度)低于1μM。
不仅如此，还观察到GSK126在6μM时显著下调了B16F10细胞的H3K27me3水平(图1C)，但在10μM时却不能有效地抑制癌细胞的增殖(图1A)。这表明当GSK126已经能够有效抑制EZH2的组蛋白甲基转移酶活性时，却不能发挥出抗肿瘤效应。
接下来，为了进一步验证10μM的GSK126对黑色素瘤细胞B16F10的效用，进行了划痕实验。与细胞增殖实验相似，培养36h后，与对照组相比，GSK126在10μM时不能有效抑制细胞迁移(图2A)。此外，为了评估GSK126的抗存活作用，用不同浓度的GSK126处理B16F10细胞不同时间，并通过流式细胞术(图2B)和活细胞荧光成像(图2C)分析了细胞的凋亡率。结果表明，10μM的GSK126诱导B16F10细胞凋亡的能力有限。由此可见，较高浓度的GSK126(10μM)处理后，实体瘤细胞B16F10、Huh7和SMMC7721的增殖以及B16F10细胞的迁移和存活没有受到明显抑制。
2.GSK126上调黑色素瘤B16F10肿瘤细胞脂肪酸水平
在发生显著变化的代谢产物中，GSK126处理组中有不少脂肪酸的水平出现上升。其中有五种多不饱和脂肪酸，包括α-亚麻酸，DHA，EPA，亚油酸和γ-亚麻烯酸)和一种单不饱和脂肪酸，包括10Z-庚二烯酸(图3)。
这表明GSK126可以提高脂肪酸丰度。这些脂肪酸可用作脂质合成的底物，以形成质膜结构，但在过度积累时会抑制细胞生长并诱导凋亡。脂肪酸的从头合成能为癌细胞的生物膜结构、能量产生和蛋白质修饰提供原料。而且，肿瘤中高LD和胆固醇酯含量与癌症侵袭能力相关。这提示脂质积累可能是GSK126抗肿瘤疗效不佳的原因。
3.调节脂质代谢可以增强GSK126对癌细胞的抑制作用
3.1GSK126治疗导致小鼠体内脂质蓄积
由于使用GSK126处理的B16F10细胞中多种脂肪酸均上调，因此探讨了荷瘤小鼠脂质代谢的改变。我们选用6-8周龄C57BL/6的小鼠进行皮下荷瘤B16F10细胞，再使用GSK126治疗。小鼠肝组织切片的H&E和油红O染色显示，GSK126治疗组的脂肪空泡和脂质沉积显著增加(图4A)。小鼠血液中甘油三酸酯(TG)的水平也明显升高(图4B)。这些结果表明，GSK126可以调节肝脏和整个身体的脂质代谢。所以，进一步检测到脂肪酸合成相关基因在GSK126处理的肝癌(HCC)细胞系SMMC7721和Huh7中的表达。如图4C-D所示，在GSK126处理下，ACLY、FASN和SCD的mRNA和蛋白质水平显著升高，这与RNA-seq数据一致。
3.2调节脂质代谢可以增强GSK126对癌细胞的抑制作用
为了验证癌细胞的脂质代谢是影响EZH2抑制剂敏感性的关键因素，使用UPLC-MS/MS系统对GSK126处理的Daudi细胞进行代谢组学分析，选用的浓度为6μM，接近IC50值。通过OPLS-DA分析发现，对照组和GSK126处理组的细胞之间代谢组差异很明显(图5a-b)。有71种变化显著的代谢物且VIP值大于1.0。与对照相比，GSK126处理的细胞中有65种上调和6种下调的代谢物(图6a，图5c)。在这些变化显著的代谢物中，我们发现GSK126处理的细胞中有四种脂肪酸减少，包括一种MUFA(蓖麻油酸)和一种PUFA(DPA n-6)(图6b)。这表明GSK126处理后血液肿瘤细胞的基础脂质代谢减弱。根据The Human Protein Atlas数据库分析，淋巴瘤中SCD1蛋白表达的阳性率低于其他实体瘤(图5d)，这能间接说明血液肿瘤细胞的基础脂质代谢不高。
与代谢组学结果一致，GSK126治疗没有上调ELOVL2、SCD1和FASN的表达(图6c)。此外，还检测了补充脂肪酸是否会降低Daudi细胞对GSK126的敏感性。通过添加棕榈酸和硬脂酸可以适度促进细胞增殖(图5e)，并且脂肪酸的补充在不同程度上挽救了被GSK126抑制的细胞活力(图6d-e)。这些结果表明癌细胞中的脂肪酸水平增加可以削弱EZH2抑制剂的抗肿瘤作用。
我们的研究结果表明，ELOVL2和SCD1直接受启动子区域上的EZH2和H3K27me3调节，这表明ELOVL2或SCD1抑制可能增强细胞对EZH2抑制剂的敏感性。由于SCD1催化饱和脂肪酸去饱和，在PUFA延伸的上游，因此在随后的研究中，使用SCD1抑制剂MF-438进行联合治疗。
相关体外实验和体内实验的简要步骤如下所示：
体外实验：
(1)将处于对数生长期的细胞使用0.25％胰蛋白酶进行消化，加入含血清的培养基终止。200g，离心5min；
(2)利用显微镜计数法制备相应浓度的单细胞悬液后，加入96孔细胞培养板中，使得每孔培养基体积为150μL(约5000个细胞)，每个处理组设置5-6个复孔；
(3)将96孔板置于细胞培养箱继续培养约12-24h，待显微镜下观察到每孔汇合度约20-30％时，弃掉培养基。然后根据实验需求，加入含有药物的培养基，设定一系列药物浓度组(如治疗B16F10细胞、SMMC7721细胞时，设置GSK126浓度为10μM，MF-438浓度为10μM)，每个处理组设置5-6个复孔；
(4)将96孔板置于细胞培养箱中检测仪器里，用IncuCyte
Live-CellAnalysis System进行检测。使用10倍物镜以3h的时间间隔，拍摄每孔内不同区域的四组相衬图像；
(5)实时监测72h后，利用IncuCyte S3图像分析软件，通过检测细胞边缘分析并确定每孔细胞的汇合度百分数，用于评估细胞增殖情况。
体内实验：
(1)制备处于对数生长期的肿瘤细胞(B16F10)单细胞悬液。利用无菌PBS作溶剂，调整细胞浓度为5.0×106个/mL；
(2)在超净工作台内，小鼠(6-8周龄的C57BL/6雌鼠，体重18-20g)用苯巴比妥钠(40mg/kg)进行麻醉，除毛，以便于荷瘤和肿瘤测量；
(3)利用注射器在小鼠背部右上区域皮下植入B16F10细胞(0.1mL的单细胞悬液)，注射局部形成明显的球状凸起；
(4)将小鼠放回饲养笼中，随后观察1-2天；
(5)当小鼠背部出现瘤体(约50mm3)后，进行随机分组(5-6只/组，分为对照组和治疗组)和药物治疗；
(6)治疗组分为GSK126单药(50mg/kg/天)、MF-438单药(20mg/kg/天)和GSK126(50mg/kg/天)与MF-438(20mg/kg/天)联合用药。治疗使用的药物GSK126、MF-438购于上海蓝木，溶剂采用说明书配方，对照组使用等量的溶剂处理。GSK126采用腹腔注射给药，MF-438采用灌胃给药，每2天使用游标卡尺测量和称量天平记录肿瘤的长(a)、宽(b)及小鼠体重变化情况；
(7)药物治疗14天后，处死小鼠并保存相应的组织样本进行下游实验。
结果表明，与GSK126或MF438单独处理72小时相比，GSK126和MF-438的组合显着抑制B16F10和SMMC7721细胞的增殖(图6f)。通过CCK-8测试和CompuSyn软件分析的CI显示两种细胞中不同浓度的GSK126和MF-438的协同作用(图6g)。体内试验表明，药物组合的预处理B16F10细胞显著降低了小鼠皮下移植瘤的生长(图6h-k)。
综上所述，上述结果表明抑制SCD1可以增强EZH2抑制剂的抗癌作用。本发明为临床上能够安全、有效、方便、经济地使用EZH2抑制剂治疗实体瘤提供一种新思路，临床应用前景良好。
显然，本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样，倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内，则本发明也意图包含这些改动和变型在内。
Claims (5)
1.一种增强EZH2抑制剂抗肿瘤作用的药物组合物，其特征在于：所述药物组合物由EZH2抑制剂和SCD1抑制剂组成，其中所述SCD1抑制剂增强所述EZH2抑制剂抗实体瘤的作用，所述实体瘤选自：黑色素瘤或肝癌，所述EZH2抑制剂为GSK126，所述SCD1抑制剂为MF-438，所述EZH2抑制剂与所述SCD1抑制剂的质量比为10：10-10：4。
2.一种增强EZH2抑制剂抗肿瘤作用的药物制剂，其特征在于：所述药物制剂由治疗有效量的权利要求1所述的药物组合物和药学上可接受的载体制成。
3.根据权利要求2所述的药物制剂，其特征在于：所述药物制剂为口服制剂，所述口服制剂是口服液、片剂、粉剂、胶囊剂或颗粒剂。
4.权利要求1所述的药物组合物或者权利要求2或权利要求3所述的药物制剂在制备抗肿瘤药物中的用途。
5.根据权利要求4所述的用途，其特征在于：所述肿瘤是实体瘤，所述实体瘤选自：黑色素瘤或肝癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111545151.1A CN114177299B (zh) | 2021-12-16 | 2021-12-16 | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111545151.1A CN114177299B (zh) | 2021-12-16 | 2021-12-16 | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114177299A CN114177299A (zh) | 2022-03-15 |
| CN114177299B true CN114177299B (zh) | 2022-08-16 |
Family
ID=80605421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111545151.1A Active CN114177299B (zh) | 2021-12-16 | 2021-12-16 | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114177299B (zh) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105541801B (zh) * | 2016-01-18 | 2018-07-17 | 常州大学 | Ezh2甲基转移酶抑制剂gsk126的合成方法 |
-
2021
- 2021-12-16 CN CN202111545151.1A patent/CN114177299B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114177299A (zh) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Afonso et al. | Competitive glucose metabolism as a target to boost bladder cancer immunotherapy | |
| Zhuang et al. | Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model | |
| Xu et al. | Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity | |
| RU2753523C2 (ru) | УЛУЧШЕННЫЙ ТЕРАПЕВТИЧЕСКИЙ ИНДЕКС ИНГИБИТОРОВ ПРОТИВ ИММУННОЙ КОНТРОЛЬНОЙ ТОЧКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЭКСТРАКТ PHY906, ЭКСТРАКТ Scutellaria baicalensis Georgi (S) ИЛИ СОЕДИНЕНИЕ ИЗ ТАКИХ ЭКСТРАКТОВ | |
| Ranasinghe et al. | A synopsis of modern-day colorectal cancer: Where we stand | |
| TW202114670A (zh) | 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途 | |
| JP2015214579A (ja) | 癌細胞アポトーシス | |
| Zhang et al. | Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2 | |
| Kong et al. | Anti-obesity effects of galacto-oligosaccharides in obese rats | |
| CN111358952A (zh) | 一种抗肿瘤药物组合物及其制剂和应用 | |
| TW201907916A (zh) | 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑 | |
| Xu et al. | Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231 | |
| Li et al. | Sinomenine hydrochloride bidirectionally inhibits progression of tumor and autoimmune diseases by regulating AMPK pathway | |
| CN114177299B (zh) | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 | |
| JP2022515249A (ja) | 癌の治療におけるドセタキセルの長期使用 | |
| TW202034919A (zh) | 西奧羅尼用於小細胞肺癌的治療 | |
| JP2022514960A (ja) | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 | |
| CN114010789B (zh) | 蟾蜍甾烯类化合物在制备治疗egfr和/或stat3驱动疾病的药物中的应用 | |
| JP2022516252A (ja) | がんを処置するための薬学的組合せ | |
| SG191926A1 (en) | Combinations | |
| WO2023108563A1 (zh) | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 | |
| CN111617081B (zh) | 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途 | |
| CN115364231B (zh) | 一种增强ezh2抑制剂抗肿瘤作用的药物组合物及其用途 | |
| WO2012074184A1 (ko) | 스핑고신-1-포스페이트 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물 | |
| CN116710095A (zh) | 一种治疗癌症的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |